Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Depreciation & Amortization (IS)Depreciation Expense EBIAT Gross Profit Leases Loans and Notes Receivables Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

InMed Pharmaceuticals (INM) Shares Issued (2021 - 2025)

InMed Pharmaceuticals has reported Shares Issued over the past 5 years, most recently at $663671.0 for Q2 2025.

For Q2 2025, Shares Issued rose 66367000.0% year-over-year to $663671.0; the TTM value through Jun 2025 reached $5.0 million, up 146.77%, while the annual FY2025 figure was $5.0 million, 3.67% down from the prior year.
Shares Issued for Q2 2025 was $663671.0 at InMed Pharmaceuticals, down from $2.9 million in the prior quarter.
Over five years, Shares Issued peaked at $12.0 million in Q3 2021 and troughed at -$10.7 million in Q2 2023.
A 5-year average of $1.8 million and a median of $846867.0 in 2024 define the central range for Shares Issued.
Biggest five-year swings in Shares Issued: crashed 307.54% in 2023 and later soared 66367000.0% in 2025.
Year by year, Shares Issued stood at $176.0 in 2021, then soared by 2695346.59% to $4.7 million in 2022, then plummeted by 325.13% to -$10.7 million in 2023, then skyrocketed by 103.71% to $396153.0 in 2024, then skyrocketed by 67.53% to $663671.0 in 2025.
Business Quant data shows Shares Issued for INM at $663671.0 in Q2 2025, $2.9 million in Q1 2025, and $396153.0 in Q4 2024.